14 results for "P. Roger"
Showing 1–14 · 0.56 seconds · RSS
-
-
-
Book Full text
Bibliothèque historique, monumentale, ecclésiastique, et littéraire, de la Picardie et de l'Artois
-
-
-
Journal Article Full text
W. Matthews Grant’s Dual Sources Account and Ultimate Responsibility
A number of philosophers and theologians have recently challenged the common assumption that it would be impossible for God to cause humans actions which are free in the libertarian or incompatibilist sense. Perhaps the most sophisticated version of this challenge is due to W. Matthews Grant. By…
-
Journal Article
Assessment of long-term kyphosis following transthoracic corpectomy with single adjacent level posterior instrumentation
Anterior thoracic spinal instrumentation has traditionally been supported by a posterior thoracic construct spanning from at least two levels above to two levels below; however, instrumentation at a single-level above and below may be adequate to support such a construct. We report two cases of…
-
Journal Article Full text
Sulfate Metabolism in Human Chondrocyte Cultures
The depletion of articular cartilage in the afflicted joints is a primary clinical feature of osteoarthritis. This disorder has been linked to a disturbance in the metabolism of the extracellular matrix components of this tissue. The mechanisms involved in the regulation of sulfated proteoglycan…
-
Journal Article Full text
CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Cell cycle progression, including genome duplication, is orchestrated by cyclin-dependent kinases (CDKs). CDK activation depends on phosphorylation of their T-loop by a CDK-activating kinase (CAK). In animals, the only known CAK for CDK2 and CDK1 is cyclin H-CDK7, which is constitutively active…
Also available at: PLOS
-
Journal Article
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Abstract Cyclin D‐CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER‐positive breast tumors. Unfortunately, no reliable…
-
Journal Article
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options. We evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines including 19 patient‐derived ones, using various approaches including RNA‐sequencing. Palbociclib strongly and durably…
-
Journal Article
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
BackgroundCDK4/6 inhibitors (CDK4/6i) have been established as standard treatment against advanced Estrogen Receptor-positive breast cancers. These drugs are being tested against several cancers, including in combinations with other therapies. We identified the T172-phosphorylation of CDK4 as the…